VIDEO: Belzutifan possible new option for refractory clear cell kidney cancer
Click Here to Manage Email Alerts
MADRID — Moshe Ornstein, MD, discussed the results of LITESPARK-005 presented at ESMO Congress in a video interview with Healio.
Ornstein, genitourinary medical oncologist at Cleveland Clinic, talked about the current standard in refractory clear cell kidney cancer and the potential of targeting hypoxia-inducible factor 2 alpha (HIF-2 alpha) for treatment.
He said the LITESPARK-005 study showed that treatment with belzutifan (Welireg, Merck), a first-in-class oral HIF-2 alpha inhibitor, led to “improvements in response rate and statistically significant improvements in PFS,” and was well-tolerated compared with everolimus in patients with previously treated advanced clear cell renal cell carcinoma.
According to Ornstein, the results showed a 25% reduction in the risk for progression for belzutifan vs. everolimus and a higher response rate (over 22% for belzutifan vs. 3.5% for everolimus).
“I do expect that this new agent of belzutifan for clear cell [renal cell carcinoma] will go through the regulatory process and ultimately be an option for our patients with refractory clear cell renal cell carcinoma,” Ornstein said.
Reference:
- Albiges L, et al. Abstract LBA88. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Click Here to Manage Email Alerts